Bejelentkezés Regisztrálj ingyen

Albireo Pharma Inc Ret. a saját tőke

Mi az Albireo Pharma Inc Ret. a saját tőke?

A Ret. a saját tőke az Albireo Pharma Inc - -97.59%

Mi a Ret. a saját tőke meghatározása?



A saját tőke megtérülése egy vállalkozás nyereségességének mértéke a részvényes saját tőkéjének könyv szerinti értékéhez viszonyítva. Ezt úgy számítják ki, hogy a pénzügyi év nettó eredményét a teljes részvényes tőkével osztják el.

The return on equity (ROE) ROE is a measure of how well a company uses investments to generate earnings growth. ROE is used for comparing the performance of companies in the same industry. It indicated the management's ability to generate income from the equity available to it. ROEs of 15-20% are generally considered good. ROEs are also a factor in stock valuation, in association with other financial ratios. In general, stock prices are influenced by earnings per share (EPS), so that stock of a company with a 20% ROE will generally cost twice as much as one with a 10% ROE.

Ret. a saját tőke a Health Care szektor a NASDAQ-on cégekben a Albireo Pharma Inc -hoz képest

Mit csinál Albireo Pharma Inc?

Albireo Pharma is a clinical-stage biopharmaceutical company focused on the development of novel bile acid modulators to treat rare pediatric and adult liver diseases, and other adult liver diseases and disorders. Albireo's lead product candidate, odevixibat, is being developed to treat rare pediatric cholestatic liver diseases with Phase 3 pivotal trials in PFIC, Alagille syndrome and biliary atresia. The Company completed IND-enabling studies for new preclinical candidate A3907 this year and plans to advance development in adult liver disease. Albireo was spun out from AstraZeneca in 2008 and is headquartered in Boston, Massachusetts, with its key operating subsidiary in Gothenburg, Sweden. The Boston Business Journal named Albireo one of the 2020 Best Places to Work in Massachusetts for the second consecutive year.

ret. a saját tőke -hoz hasonló cégek Albireo Pharma Inc